Immunologic Factors: all 3,292 studies that test it
Page 2 of 33. Open to participants first (386), then studies with results posted, then the rest; newest registration first within each.
- Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT)RecruitingNCT07202052Phase 2/3
- Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL TreatmentRecruitingNCT07199296Phase 2
- Efficacy and Safety of the RD Regimen(Lenalidomide, Dexamethasone) for Rosai-Dorfman DiseaseRecruitingNCT07187167Phase 2
- Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström MacroglobulinemiaNot yet recruitingNCT07169565Phase 1
- Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder ArthroplastyRecruitingNCT07138898Phase 2
- A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT07138209Phase 3
- Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell LymphomaRecruitingNCT07126236Phase 2
- Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin LymphomaRecruitingNCT07097363Phase 2
- Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple MyelomaRecruitingNCT07096778Phase 2
- A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for TransplantRecruitingNCT07095452Phase 2/3
- A Randomized Controlled Study of the Efficacy and Safety of Lenalidomide in the Treatment of Active IgG4-related DiseaseRecruitingNCT07068165Phase 2/3
- A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)RecruitingNCT07059000Phase 3
- The Holistic StudyNot yet recruitingNCT07051915Phase 3
- Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB)RecruitingNCT07048262Phase 2
- Immunotherapy of the Recent-onset Type 1 Diabetes in Adolescents With Repeated Courses of RituximabRecruitingNCT07041268Phase 2
- A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1Not yet recruitingNCT07034508Phase 2
- A Study to Learn More About the Effects and Safety of JMT601 in Adults With Primary Membranous NephropathyNot yet recruitingNCT07029139Phase 2
- Fenofibrate Role in the Prophylaxis From Peripheral Neuropathy Induced by Bortezomib, Lenalidomide and Dexamethasone (VRd) Protocol in the Treatment of Patients With Multiple Myeloma (MM)RecruitingNCT07025005Phase 4
- The Efficacy and Safety of the Combination Therapy of Daratumumab, Cabozantinib, Pomalidomide, and Dexamethasone (D-KPd) in the Treatment of High-risk First-time Relapsed or Primary Refractory MM PatientsNot yet recruitingNCT07015021Not applicable
- ERd Combination Treatment in Newly Diagnosed Multiple Myeloma (ADVANCE 2.0)RecruitingNCT06997081Phase 2
- Phase 1b/2a Trial of Allogeneic HSCT From an HLA-partially Matched Related or Unrelated Donor After TCRab+ T-cell/CD19+ B-cell Depletion for Patients With Monogenic and/or Early-onset Medically Refractory Crohn DiseaseNot yet recruitingNCT06986382Phase 1/2
- Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW)RecruitingNCT06983821Phase 3
- Phase I Study of Cosibelimab and Balixafortide in Metastatic Pancreatic Ductal AdenocarcinomaNot yet recruitingNCT06981806Phase 1
- A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple MyelomaRecruitingNCT06980480Phase 3
- Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)RecruitingNCT06977711Phase 1
- Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple MyelomaRecruitingNCT06974786Phase 2
- ZR-MTX for PIOL Phase II TrialRecruitingNCT06973811Phase 2
- Lenalidomide vs Methotrexate in Difficult-to-treat Cutaneous Lupus ErythematosusNot yet recruitingNCT06965244Phase 3
- V-IMMUNE: A Novel Immunoglobulin Therapy for ImmunodeficiencyRecruitingNCT06954441Phase 3
- Study of the Efficacy and Safety for Rituximab in Myalgia Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)RecruitingNCT06952413Phase 2
- A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)RecruitingNCT06943872Phase 3
- Zanubrutinib Combined With BR in the First-line Treatment of Waldenström's MacroglobulinemiaNot yet recruitingNCT06942507Not applicable
- A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)RecruitingNCT06935357Phase 3
- IVIG Trial for the Treatment of Bronchopulmonary DysplasiaRecruitingNCT06925360Phase 2
- Sequential PEG-IFN for HBV After Ending RNA-targeted RegimensRecruitingNCT06923280Not applicable
- Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM PatientsRecruitingNCT06918002Phase 3
- Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After RelapseRecruitingNCT06910124Phase 2
- Evaluation of 200 mg of Rituximab Every 6 Months as Maintenance Treatment of Rituximab-treated Patients With Rheumatoid ArthritisRecruitingNCT06906549Phase 4
- A Phase I Clinical Trial of CAR-T Cells for Advanced Gynecological Solid TumorsRecruitingNCT06904131Not applicable
- A Trial on the Treatment of Bronchial Asthma With Budesonide Formoterol Combined With Immune Modulators (Staphylococcus and Neisseria Tablets)Not yet recruitingNCT06895460Phase 3
- A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in CombinationsRecruitingNCT06892522Phase 1/2
- SBRT Plus Lenalidomide for Solitary Plasmacytoma: Phase II TrialRecruitingNCT06863584Phase 2
- Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell LymphomaRecruitingNCT06846489Phase 2
- Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell LymphomaRecruitingNCT06839053Phase 2
- Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell TherapyRecruitingNCT06834373Phase 2
- Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis BullosaRecruitingNCT06834035Phase 1/2
- Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCLRecruitingNCT06803693Phase 2
- MZL-IPI Risk-adapted Targeted Therapy in Untreated MZLRecruitingNCT06793189Phase 2
- HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZLRecruitingNCT06792825Phase 2
- Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL)RecruitingNCT06788964Phase 2
- A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple MyelomaRecruitingNCT06768489Phase 1
- Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients.RecruitingNCT06762431Phase 1/2
- Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell LymRecruitingNCT06760156Phase 2
- A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% KIg10 (QIVIGY) in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)RecruitingNCT06752356Phase 3
- A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)RecruitingNCT06747351Phase 3
- Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell LymphomaRecruitingNCT06723457Phase 2
- Rituximab Induced Remission in Patients With Chronic Inflammatory Demyelinating PolyneuropathyRecruitingNCT06714838Phase 3
- Treatment of Presymptomatic (Stage 1) Type 1 Diabetes Pediatric Patients With Treg Cell Preparations and Anti-CD20 AntibodyRecruitingNCT06688331Phase 2
- NK010 or NK042 in Combination With Rituximab for Refractory Systemic Lupus Erythematosus/Lupus NephritisRecruitingNCT06676631Phase 1
- An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab TreatmentRecruitingNCT06675955Phase 3
- Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell LymphomaRecruitingNCT06649812Phase 2
- Avacopan vs Reduced-dose Glucocorticoids in ANCA-associated VasculitisRecruitingNCT06611696Phase 4
- Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR)RecruitingNCT06607549Phase 1
- The MIGHT Trial - An Exploratory Clinical Trial of IVIG in Anti-HMGCR Immune Mediated Necrotizing MyopathyRecruitingNCT06599697Phase 2
- The Effect of Rituximab on Cognitive and Hand Functions in Secondary Progressive Multiple SclerosisRecruitingNCT06599307Phase 2
- R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell LymphomaRecruitingNCT06594640Phase 1/2
- Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.RecruitingNCT06581562Phase 1
- Prednisone Plus IVIg vs. Prednisone for ITP During PregnancyRecruitingNCT06577909Phase 2
- A Phase III Clinical Trial of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Treatment of Male Patient With Newly Diagnosed Advanced DLBCLNot yet recruitingNCT06573645Phase 3
- Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell LymphomaRecruitingNCT06572618Phase 2
- Epco, Zanu, Ritux for R/R FL or MZLRecruitingNCT06563596Phase 2
- Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WMRecruitingNCT06561347Phase 2
- MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin LymphomaNot yet recruitingNCT06557330Phase 2
- A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell LymphomaRecruitingNCT06554600Phase 2
- A Study of Pomadomide in Combination With Rituximab and Methotrexate for Newly-diagnosed Primary Central Nervous System LymphomaRecruitingNCT06554561Phase 1/2
- Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Patients with Follicular Lymphoma (FL)Not yet recruitingNCT06549335Phase 2
- Evaluation of Efficacy and Safety of Rituximab and Mycophenolate Mofetil Combination in Patients With Interstitial Lung Disease Related to Systemic SclerosisRecruitingNCT06549231Phase 3
- A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)RecruitingNCT06533098Phase 3
- Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCLRecruitingNCT06530511Phase 2
- N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With NeuroblastomaRecruitingNCT06528496Phase 2
- The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell LymphomaRecruitingNCT06522555Phase 3
- Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell LymphomaRecruitingNCT06521255Phase 3
- A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCLNot yet recruitingNCT06516978Phase 2
- Rituximab Plus Venetoclax in Front Line Marginal Zone LymphomaRecruitingNCT06510309Phase 2
- Bendamustine and Rituximab With or Without Orelabrutinib in MCL TreatmentRecruitingNCT06496308Phase 3
- Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple SclerosisEnrolling by invitationNCT06495593Phase 4
- Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular LymphomaRecruitingNCT06471738Phase 2
- Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple MyelomaRecruitingNCT06461988Phase 2
- Daratumumab/Daratumumab and Hyaluronidase-fihj in Combination With Pomalidomide and Dexamethasone for the Treatment of Patients With Newly Diagnosed AL Amyloidosis: a Prospective, Multicenter, Single-arm StudyRecruitingNCT06455748Not applicable
- Precision Administration of Anti-thymocyte Globulin With or Without VerapamilRecruitingNCT06455319Phase 2
- Nituzumab Plus Serplulimab Combined With SBRT in Cervical CancerRecruitingNCT06455072Phase 2
- Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.RecruitingNCT06454968Phase 2
- Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCLNot yet recruitingNCT06441097Phase 2
- Role of Immunoglobulin in Male InfertilityRecruitingNCT06423989Not applicable
- MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell LymphomaRecruitingNCT06414148Phase 2
- Belimumab After Rituximab in Resistant Primary Juvenile SSRecruitingNCT06410833Phase 4
- Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease DetectionRecruitingNCT06409702Phase 4
- Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)RecruitingNCT06390956Phase 2
- Daratumumab for Patients With Light Chain AmyloidosisRecruitingNCT06376214Not applicable
- Rituximab and Zanubrutinib in Patients With Indolent B-cell LymphomasRecruitingNCT06350318Phase 2